Atherosclerotic disease is the major cause of death and disability in much of the world. Identifying genetic? and environmental contributions to disease susceptibility is a current challenge requiring clinical and animal? model studies. The creation of induced mutant mouse models susceptible to atherosclerosis has heralded a? new era of research into the genetics of this disease. Not only can candidate genes be tested directly, but? new genes and pathways can be identified by quantitative trait locus (QTL) mapping. In crosses? betweenC57BL/6J and FVB/N mice on the apo E knockout background, a very strong proximal chromosome? 10 atherosclerosis susceptibility locus was identified. Unexpectedly, the genotypic means for aortic root? lesion area for markers at this locus indicated homozygosity for the FVB/N allele was associated with? increased atherosclerosis compared to heterozygosity and homozygosity for the C57BL/6J allele. This? finding was confirmed by characterizing congenic lines encompassing the 0 to 21.9cM region. Now, eight? subcongenic lines have also been characterized and it appears the locus is complex with one gene between? 11.4 and 19.6 Mb (10a) and another between 20.0 and 22.3 Mb (10b). A promising candidate gene in the? 10a region, named A20, has been studied. A20 is a gene turned on by the TNFa/NFkB pathway, which then? acts to shut down signaling through the pathway. C57BL76J and FVB/N A20 were shown to differ at a single? codon and after TNFa stimulation FVB/N A20 was much more effective at shutting down the TNFa/NFkB? pathway than C57BL/6J A20. The TNFa/NFkB pathway is both proinflammatory and antiapoptotic and could? influence atherosclerosis by either mechanism.
The specific aims of this proposal are to identify the causal? genes in the 10a and 10b regions by further defining the critical intervals with additional subcongenic lines,? sequencing and expression analysis of genes within these intervals, and the creation of induced mutant? mouse lines for promising genes to prove causation. In addition, the role of A20 in atherosclerosis will be? further explored in induced mutant mice and mechanistic studies will be carried out in whole animal and? tissue culture studies. Particular attention will be paid to how the functional difference between C57BL/6J? and FVBV/N A20 may act to alter the balance between TNFa mediated inflammation and apoptosis and how? this might affect atherosclerosis progression. We anticipate that these studies will shed light on new genes? and pathways that control atherosclerosis susceptibility, which may lead to improved diagnosis of? susceptible individuals in the population, and someday to novel mechanism based therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054591-13
Application #
7585683
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
13
Fiscal Year
2008
Total Cost
$537,526
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications